Related Experiment Video
Updated: Mar 11, 2026

Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
Published on: July 28, 2018
Continuous Versus Intermittent Loop Diuretics Step-by-Step Protocol in Acute Heart Failure (DIUR-AHF):
Gaetano Ruocco1,2, Andrea Salzano3,4,5, Sara Franceschi6
1Cardiovascular Research Institute Maastricht Maastrict University Maastricht Netherlands.
Insights
High-dose loop diuretics in acute heart failure increase adverse events and reduce effectiveness. This contrasts with low-dose treatment, suggesting caution with high-dose strategies for better patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Loop diuretics are standard treatment for acute heart failure (AHF) congestion.
- Optimal dosing and administration strategies remain unclear.
Purpose of the Study:
- To compare intermittent versus continuous furosemide infusion.
- To evaluate high-dose (HD) versus low-dose loop diuretics.
- To assess effects on congestion, renal function, and clinical outcomes in AHF.
Main Methods:
- Analysis of the DIUR-AHF study data.
- 370 AHF patients received either continuous or intermittent IV loop diuretics for 72-120 hours.
- HD defined as >120 mg/day; outcomes assessed over 6-month follow-up.
Main Results:
- HD loop diuretics showed similar congestion relief but reduced diuretic efficiency compared to low-dose.
- HD group experienced significantly more adverse events (55% vs 20%).
- Multivariable analysis linked HD treatment to poorer postdischarge outcomes (HR 1.95).
Conclusions:
- High-dose loop diuretics in AHF increase adverse event risk and decrease diuretic response.
- Findings align with previous research on HD diuretics and prognosis in chronic heart failure.
- Further research needed on loop diuretic response with other decongestive therapies.
Background:
Loop diuretics are used to solve congestion in acute heart failure. However, a clear indication about the best infusion modality, dose, and duration of the treatment has not yet been established. In this analysis of the DIUR-AHF (Different Loop Diuretic Dosing and Administration in Acute Heart Failure) study, we aimed to investigate the effects of different diuretic administration modalities (ie, intermittent versus continuous furosemide infusion) and dose (high dose [HD] versus low dose) on congestion, renal function, and outcome.
Methods:
Patients received intermittent or continuous intravenous loop diuretics infusion combined as a 1:1 ratio for a period of 72 to 120 hours. HD was defined as a high loop diuretic dose >120 mg/d. Clinical outcome was evaluated in terms of death or heart failure rehospitalization over a 6-month follow-up period.
Results:
A total of 370 patients with AHF were included in this analysis, 189 treated with continuous intravenous loop diuretics infusion and 181 with intermittent intravenous loop diuretics infusion. At baseline, the continuous intravenous loop diuretic infusion group showed increased median values of blood urea (P=0.010) and creatinine (P=0.017). Dividing our sample according to loop diuretic dosage, the HD group revealed similar congestion and weight loss compared with the low-dose group; however, the HD group showed a reduced diuretic efficiency (-0.13 [-0.22 to -0.07] versus -0.32 [-0.59 to -0.20] kg/d; P<0.001) and an increased rate of adverse event occurrence (55% versus 20%; P<0.001). Multivariable analysis showed the association between HD treatment and poor postdischarge outcome (hazard ratio, 1.95 [95% CI, 1.23-3.10]; P=0.005).
Conclusions:
An HD of loop diuretics infusion revealed an increased risk for adverse events together with reduced diuretic response. Our results extend previous findings revealing the association between HD diuretics and prognosis in patients with chronic HF. Additional studies may confer loop diuretic response in relation to the other decongestive treatments.
Related Concept Videos
Heart Failure Drugs: Diuretics
Acute Kidney Injury V: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Continuous Renal Replacement Therapy

